The Caledonian-Record

Subcutaneous PD-1 Inhibitors Transition from Novelty to Routine Care as Oncologists Tailor Use ...

The U.S. market for PD-1 inhibitors has entered a new phase of evolution. According to the latest RealTime Dynamix™: PD-1 Inhibition in ...

Subcutaneous PD-1 Inhibitors Transition from Novelty to Routine Care as Oncologists Tailor Use by Tumor Type, According to Spherix Global Insights

Oncologists have moved beyond evaluating subcutaneous PD-1 inhibitors as convenient alternatives to intravenous therapy, instead incorporating them into disease-specific treatment strategies as ...

Will Keytruda Remain the Driving Force Behind Merck's Q2 Performance?

Detailed price information for Roche Holding Ltd ADR (RHHBY) from The Globe and Mail including charting and trades.
Solicitors Journal

Patents Court rejects MSD's bid for wider Mayne Pharma disclosure in Halozyme hyaluronidase dispute

The Patents Court has dismissed an application by Merck Sharp & Dohme (UK) Limited seeking further disclosure of experimental ...